Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGE	S IN BENEFI	CIAL OW	/NERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  COX GEOFFREY F						2. Issuer Name and Ticker or Trading Symbol Biota Pharmaceuticals, Inc. [ BOTA ]									k all applic	cable)	g Pers	son(s) to Iss 10% Ov	
(Last) 12270 W	(F TLKINS A	*	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/01/2013									Officer below)	(give title		Other (s below)	specify
(Street)	ILLE M	ID	20852		4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								i. Indi ine) X					
(City)	(S	state)	(Zip)		=	Person Person													
		Tak	le I - Nor	ı-Deriv	/ativ	e Se	curities	s Ac	quired, I	Disp	osed c	f, or Be	nefici	ally	Owned				
1. Title of Security (Instr. 3)  2. Trans Date (Month/				action 2A. Deemed Execution Date, if any (Month/Day/Year)			Code (Ir	Transaction Disposed Of (D) (Instr. 3, 4) Code (Instr. 5)			ed (A) o tr. 3, 4 a	4 and Securit		es Following (I)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Pric	rice Transac (Instr. 3		tion(s)			(iiisti. 4)
			Table II -						uired, Di , option:						Owned				
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any		Date, Transaction Code (Instr.			n of l		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security		9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		xpiration vate	Title	Amou or Numb of Share	er					
Stock Option (Right to Buy)	\$4.05	05/01/2013			A		15,000		(1)	0	5/01/2013	Common Stock	15,00	00	\$0.00	15,00	0	D	

## **Explanation of Responses:**

1. This option vests and becomes exercisable in 12 equal monthly installments commencing on June 1, 2013.

## Remarks:

/s/ Peter Azzarello, Attorney-

in-fact

\*\* Signature of Reporting Person

05/02/2013 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Russell H. Plumb and Peter Azzarello, and each of them individually, his true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% or greater stockholder of Biota Pharmaceuticals, Inc. (the "Company"), any and all Form 3, 4 and 5 reports required to be filed by the undersigned in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 report and timely file such report with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary, and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that no such attorney-in-fact, in serving in such capacity at the request of the undersigned, is hereby assuming, nor is the Company hereby assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Form 3, 4 and 5 reports with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney hereby revokes and replaces any prior power of attorney granted with respect to the undersigned's holdings of and transactions in securities issued by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 2nd day of May, 2013.

/s/ Geoffrey F. Cox Signature

Geoffrey F. Cox Print Name